The first biotech recognition program focused oncompanies with the potential to change how pharmaoperates, not just discovering or developing asuccessful drug.​

Three award categories recognizing ground-breaking​ discovery and innovation​. Apply here:

Judging panel: multi-stakeholder influencers​.

Emine Yurdusever Temizkan: Biotech Leader​

• Vice President, Global Lead​
  – Lung Cancer Portfolio BioNTech​
• Prominent global pharmaceutical​
  executive specializing in oncology,​
  commercial strategy, and product development. ​
• Her professional work is heavily anchored in thoraciconcology, advancing clinical innovations for lungcancer patients, and scaling cancer immunotherapypipelines globally​

Sam Williams: Strategic Investor

• Chairman, Director, Investor Life Sciences​
• Board member of several UK Life Science companies,including Istesso, Apollo Therapeutics,Genomics, Microbiotica, Storm Therapeutics,Pulmocide, Gripable and Autifony Therapeutics​

Elisabeth Van Sant Hoffman: Pharmaceutical Expert​

• Senior Vice President, PortfolioManagement and Clinical Design andDelivery, Eli Lilly​
• Oversees portfolio and project management, clinicaldevelopment, R&D strategy, decision sciences, andclinical design and capabilities​

Dr. Alexander Gray: ​Industry Expert

• Chief Medical Officer, IDEA Pharma ​
• Pharmaceutical strategy expert​
• Trained physician and immunologist​
• Led over 100 clinical development programs, shapingstrategy and positioning of biopharma assets fromearly-stage trials through to commercialization​
• Specializes in clinical trial design, biostatistics,mechanistic pharmacology, and drug developmentstrategy across oncology, neuropsychiatry, andimmunology ​

Categories:

Platform Pioneer​

For companies building technologies capable of generating multiple future medicines​

Examples​

• AI-first drug discovery​
• Synthetic biology​
• Gene editingplatforms​

Disease Challenger​

For companies tackling diseases considered difficult, neglected, or previously untreatable​

Examples​

• Rare diseases​
• Neurodegeneration​
• Aging-related diseases

Modality Disruptor​

For companies pioneering new therapeutic modalities​

Examples​

• In vivo editing​
• RNA medicines​
• Microbiometherapeutics​